| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $794.3M | +66.6% |
| SG&A Expense | $129.4M | +39.3% |
| Operating Income | -$923.7M | -62.2% |
| Income Tax | $0 | — |
| Net Income | -$766.6M | -65.2% |
| EPS (Basic) | -$5.63 | -48.2% |
| EPS (Diluted) | -$5.63 | -48.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $174.0M | -55.2% |
| Short-term Investments | $1.39B | +2.0% |
| Current Assets | $1.63B | -9.0% |
| Total Assets | $3.00B | -14.5% |
| Current Liabilities | $205.8M | +46.8% |
| Total Liabilities | $317.2M | +54.4% |
| Stockholders' Equity | $2.69B | -18.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$655.6M | -44.8% |
| Capital Expenditures | $13.7M | -38.9% |
| Investing Cash Flow | $437.4M | +121.8% |
| Financing Cash Flow | $2.0M | -99.9% |
| Free Cash Flow | -$669.3M | -40.9% |